Quellen Reizdarm, SIBO, FODMAP
REIZDARM
Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/
Update on Irritable Bowel Syndrome Diagnostics and Therapeutics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/
Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)
https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/
25 % aller Nicht-Antibiotika schädigen Darmbakterien
https://www.ernaehrungsmedizin.blog/2018/03/20/hunderte-medikamente-schaedigen-darmbakterien/
Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome (IBS).
https://www.ncbi.nlm.nih.gov/pubmed/30611316
A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.
https://www.ncbi.nlm.nih.gov/pubmed/30406392
Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
https://www.ncbi.nlm.nih.gov/pubmed/28451914
Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)
https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/
Review of rifaximin as treatment for SIBO and IBS
https://www.ncbi.nlm.nih.gov/pubmed/19243285
Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.
https://www.ncbi.nlm.nih.gov/pubmed/29508268
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/11151884/
IBSchek – The First Clinically Validated Blood Test for IBS with Predominant Diarrhea (IBS-D) and Mixed Symptoms (IBS-M)
http://www.commdx.com/irritable-bowel-syndrome.html
Proton pump inhibitors (PPI) therapy and risk of C. diff. infection: Systematic review and meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643276/
Launch of ibs-smart™, an advancement in blood testing for Irritable Bowel Syndrome (IBS)
SIBO
How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach
https://www.ncbi.nlm.nih.gov/pubmed/26780631
Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.
https://www.ncbi.nlm.nih.gov/pubmed/29508268
A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.
https://www.ncbi.nlm.nih.gov/pubmed/30406392
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
https://www.ncbi.nlm.nih.gov/pubmed/21208106
Treatment of SIBO
http://www.townsendletter.com/FebMarch2015/sibo0215_2.html
Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/11151884/
Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/22523730
Review of rifaximin as treatment for SIBO and IBS
https://www.ncbi.nlm.nih.gov/pubmed/19243285
Update on Irritable Bowel Syndrome Diagnostics and Therapeutics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/
Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504364/
Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system.
https://www.ncbi.nlm.nih.gov/pubmed/20852272
A 14-day elemental diet is highly effective in normalizing the lactulose breath test
https://www.ncbi.nlm.nih.gov/pubmed/14992438
Two Independent Networks of Interstitial Cells of Cajal Work Cooperatively with the Enteric Nervous System to Create Colonic Motor Patterns
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153851/
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
https://www.ncbi.nlm.nih.gov/pubmed/20937045
Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system (also known as Saccharomyces cerevisiae HANSEN CBS 5926)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027949/
FODMAP
Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs
https://www.ncbi.nlm.nih.gov/pubmed/28740352
A diet low in FODMAPs reduces symptoms of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/24076059
Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467063/
Kluyveromyces marxianus-Hefe ermöglicht die Herstellung von FODMAP-armem Vollkornbrot
https://www.ncbi.nlm.nih.gov/pubmed/30166134
Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/21615553
Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918736/
